Staar Surgical

STAA shares were up 11% at $70.91 per share as the market opened today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down 0.4%.

The Lake Forest, California-based ocular implant company posted profits of $9.6 million, or 19¢ per share, on sales of $63.2 million for the three months ended April 1, 2022, for a 92.3% bottom-line gain on sales growth of 24.5%.

Adjusted to exclude one-time items, earnings per share were 29¢, 14¢ ahead of Wall Street, where analysts were looking for sales of $60.5 million.

“Our first quarter results represent a new record for quarterly net sales and quarterly ICL units as we successfully raise surgeon and patient awareness and enthusiasm for the Visual Freedom provided by our proprietary Evo Visian ICL …

Staar Surgical today announced the first implants of the Evo Visian implantable Collamer lens in the U.S.

Lake Forest, California-based Staar Surgical designed the Evo biocompatible implantable lens for the correction of myopia and myopia with astigmatism. The first implant was performed in a woman with myopia and astigmatism in her thirties who previously used monthly disposable contact lenses and glasses. She received toric Evo ICL lenses for visual freedom and to eliminate the need for contact lenses and glasses.

The bilateral Evo implantation procedure was completed in approximately 7-8 minutes for each eye.

“We are thrilled to begin commercialization of our Evo lenses in the U.S. and announce milestone first implants just days after product approval,” Caren Mason, president and CEO, said in a news release. “The U.S. is a very important market for Staar as it represents over 20% of global refractive procedures. U.S. surgeon enthusiasm is at an all-ti…

Staar Surgical (NSDQ:STAA) posted fourth-quarter results this week that beat the earnings consensus on Wall Street and missed revenue estimates.

The Lake Forest, California-based company reported profits of $4.9 million, or 10¢ per share, on sales of $59 million for the three months ended Dec. 31, 2020, for a bottom-line gain of 47.9% on sales growth of 28.27% compared with Q4 2020.

Adjusted to exclude one-time items, earnings per share were 19¢, 3¢ ahead of The Street, where analysts were looking for sales of $59.21 million.

“Our fiscal 2021 results reflect record levels of sales, profit and growth achievement for Staar, driven by continued accelerating demand for our implantable Collamer lenses,” president and CEO Caren Mason said in a news release.

Staar Surgical did not provide a financial outlook for fiscal year 2022.

Shares in STAA were up 13.91% to $71.75 apiece in afternoon trading.